Healthcare
LIST1000Related Stocks
News
Bill Ackman Returns to Netflix After $400 Million Loss, Takes Positions in Visa and Mastercard
TradingKey - Billionaire investor Bill Ackman's Pershing Square revealed in its latest disclosure that the firm initiated a new position in Netflix (NFLX) in the second quarter, while also buying Visa (V), Mastercard (MA), S&P Global (SPGI), Intercontinental Exchange (ICE), and Alcon (ALC), adding a total of six companies.
Buffett’s Top Holdings Drive Berkshire Shares to Eight-Month High Ahead of Q2 Earnings
TradingKey - On July 28 ET, Berkshire Hathaway Class B shares (BRK.B) closed at $512.37, marking the highest closing price since November 28 of last year ($513.81), but remaining approximately 5% below the all-time closing high of $539.80 reached on May 2, 2025. Class A shares (BRK.A) also trended higher, closing at $768,010 on Tuesday, with an all-time high of $809,350 recorded on the same day.
AstraZeneca, Bristol Myers Squibb in Merger Talks to Create Nearly $400 Billion Pharma Giant
TradingKey - British pharmaceutical giant AstraZeneca (AZN) is in talks with its U.S. peer Bristol Myers Squibb (BMY) regarding a potential merger. If a deal is reached, the combined market capitalization of the two entities would approach $400 billion, potentially creating one of the world's largest pharmaceutical groups.
Novo Nordisk Falls Over 10% in Largest Single-Day Drop in Nearly Five Months After Announcing Heart Drug Trial Failure
On July 31, Eastern Time, Novo Nordisk (NVO) fell more than 10% at one point, marking its largest single-day decline since February 23, 2026. As of press time, the stock remained down 8.84% at $47.05. Novo Nordisk announced on Friday that its high-profile investigational heart drug, ziltivekimab, failed to meet the primary endpoint in a large-scale late-stage clinical trial.
NovoCure (NVCR) Breaks Out on Q2 2026 Earnings - Optune Pax Driving Recovery
TradingKey - NovoCure surged to $19.91 after Q2 2026 earnings released this morning. Revenue consensus was $172M growing 8.6% YoY. The story is Optune Pax's FDA approval and multi-indication expansion after June's TRIDENT trial disappointment. Here is the setup.
Novo Nordisk Sues Eli Lilly for False Advertising: Weight-Loss Drug Data War Escalates, GLP-1 $100 Billion Market Fight Heats Up
TradingKey - Novo Nordisk (NVO) has officially filed a lawsuit in the U.S. District Court for the District of New Jersey, alleging that Eli Lilly’s (LLY) advertisements for its blockbuster weight-loss drug Zepbound and diabetes injection Mounjaro are misleading and violate federal and state laws concerning false advertising and unfair competition. The essence of the lawsuit is a data war between the two pharmaceutical giants over the multi-hundred-billion-dollar GLP-1 drug market, where the key weapon on the battlefield is a set of clinical comparison data alleged to be "outdated."